Breaking News Instant updates and real-time market news.

AMRN

Amarin

$14.77

-3.04 (-17.07%)

, MRK

Merck

$85.51

0.75 (0.88%)

07:35
08/12/19
08/12
07:35
08/12/19
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Friday in Amarin (AMRN), Merck (MRK), AbbVie (ABBV), and Viacom (VIAB).

AMRN

Amarin

$14.77

-3.04 (-17.07%)

MRK

Merck

$85.51

0.75 (0.88%)

ABBV

AbbVie

$65.58

0.17 (0.26%)

VIAB

Viacom

$30.01

-0.78 (-2.53%)

  • 15

    Aug

  • 05

    Sep

  • 09

    Sep

  • 16

    Sep

  • 20

    Sep

  • 28

    Sep

  • 02

    Oct

  • 29

    Oct

AMRN Amarin
$14.77

-3.04 (-17.07%)

08/09/19
CANT
08/09/19
NO CHANGE
Target $35
CANT
Overweight
Amarin selloff on surprise FDA panel meeting overdone, says Cantor Fitzgerald
Amarin's announcement last night that the FDA plans to hold an advisory committee meeting, tentatively scheduled for November 14, came as a surprise, Cantor Fitzgerald analyst Louise Chen tells investors in a research note titled "No Heartbreak Here, Negative Reaction To AdCom Is Overdone, In Our View." That being said, the stock weakness in reaction to the news is overdone, says Chen. Amarin shares are down 21%, or $3.66, to $14.15 in premarket trading. The potential three-month extension to the FDA action date does not impact Vascepa's potentially multi-billion dollar peak sales opportunity, argues the analyst. Chen keeps an Overweight rating on Amarin with a $35 price target.
08/09/19
HCWC
08/09/19
NO CHANGE
Target $51
HCWC
Buy
Amarin FDA panel driven by agency's conservative approach, says H.C. Wainwright
The FDA's decision to host an Advisory Committee meeting could be driven more by the agency's conservative approach to an expanded cardiovascular event risk reduction label potentially impacting tens of millions of Americans, than any immediate concerns regarding Amarin's REDUCE-IT results themselves, H.C. Wainwright analyst Andrew Fein tells investors in a research note. Management noted the expanded Vascepa label has the potential to be the first indication to impact as many as a third of American adults, and along these lines the FDA holding an AdCom "represents vigilance above all else," contends the analyst. He continues to emphasize that the current stage of commercial development "could potentially represent just the tip of the iceberg for Vascepa." Fein downplays the significance of the AdCom in terms of "materially influencing" the overall approval path for Vascepa's expanded label and reiterates his belief of Vascepa "as a game changing drug." He believes the AdCom timing can be quantifiably valued and is "only worth" approximately a $2-$3 potential hit to his price target of $51. Fein reiterates a Buy rating on Amarin.
08/09/19
JEFF
08/09/19
NO CHANGE
Target $30
JEFF
Buy
Amarin selloff on FDA panel a buying opportunity, says Jefferies
Jefferies analyst Michael Yee views today's selloff in shares of Amarin as a buying opportunity. It is reasonable to have a drug this big discussed in public forum, Yee tells investors in a research note. While the FDA panel brings "some new risk," the corresponding stock selloff more than reflecting this, says Yee. He sees a "buying opportunity since approval is very likely." Yee reiterates a Buy rating on Amarin with a $30 price target.
08/01/19
SBSH
08/01/19
NO CHANGE
Target $23
SBSH
Buy
Amarin shares already pricing in Vascepa label expansion, says Citi
Citi analyst Joel Beatty agrees with Amarin that an FDA panel for the Vascepa label expansion is unlikely given that less than two months remain until the action date of September 28. However, approval of a cardiovascular risk reduction claim for Vascepa is already priced in to the stock, Beatty tells investors in a research note. As such, the analyst does not expect much stock movement around the PDUFA date. Upside would be if a very broad label is granted, such as no triglyceride level cutoff, says Beatty. The analyst believes that for Amarin shares to reach his unchanged price target of $23, Vascepa sales need to reach his 2020 sales projection of $769M, which is a 91% increase above the current annual run rate of $401M. This is realistic, however, given the direct-to-consumer advertising planned to begin in Q2 of 2020, as many primary care physicians "relatively unfamiliar" with Vascepa will begin to be repeatedly asked about it by patients, contends the analyst. He keeps a Buy rating on Amarin. The stock closed Wednesday up 15c to $18.59.
MRK Merck
$85.51

0.75 (0.88%)

08/07/19
ARGS
08/07/19
NO CHANGE
Target $105
ARGS
Buy
Merck price target raised to $105 from $95 at Argus
Argus analyst David Toung raised his price target on Merck to $105 and kept his Buy rating after its "strong" Keytruda-driven Q2 earnings beat, also boosting his FY19 and FY20 EPS view by 16c and 10c to $4.89 and $5.35 respectively. The analyst sees Merck's "blockbuster" Keytruda drug on track for additional indications in the U.S., Japan, China and Europe, with additional growth drivers coming from its Gardasil, Bridion, Lynparza, and Lenvima programs.
07/17/19
RAJA
07/17/19
NO CHANGE
RAJA
Investors shouldn't overreact to drug proposal headlines, says Raymond James
Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/22/19
OPCO
07/22/19
DOWNGRADE
OPCO
Perform
Oppenheimer downgrades Intec Pharma after 'major setback' of trial miss
As previously reported, Oppenheimer analyst Jay Olson downgraded Intec Pharma (NTEC) to Perform from Outperform after the company announced "a major setback" as the ACCORDANCE study did not achieve statistical superiority to Sinemet on the primary endpoint of reduction in daily OFF time. He noted that the company still has additional opportunities with other drugs, including proprietary partnerships with Novartis (NVS) and Merck (MRK), but said the read across from AP-CD/LD to other AP applications in different diseases is uncertain following this morning's news.
ABBV AbbVie
$65.58

0.17 (0.26%)

07/26/19
PIPR
07/26/19
NO CHANGE
Target $80
PIPR
Neutral
Piper still skeptical of Allergan deal despite 'great' AbbVie results
Piper Jaffray analyst Christopher Raymond says AbbVie's (ABBV) strategic questions haven't dissipated this morning's "great quarter by almost any measure." The upside in Q2 was driven by Humira and inaugural Skyrizi sales, Raymond tells investors in a post-earnings research note. The analyst, however, remains skeptical of the strategic merits of the Allergan (AGN) combination. As such, he maintains a Neutral rating on AbbVie with an $80 price target.
07/26/19
PIPR
07/26/19
NO CHANGE
PIPR
Neutral
AbbVie trial discontinuation adds risk to Biogen pipeline, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond is "incrementally cautious" on Biogen (BIIB) shares after AbbVie (ABBV) announced its anti-tau antibody Phase 2 trial in progressive supranuclear palsy was discontinued for futility. Biogen's anti-tau antibody BIIB092 is currently in a Phase 2 progressive supranuclear palsy trial with a readout anticipated by year-end 2019, Raymond tells investors in a research note. While the analyst does not model this opportunity, he points out that Biogen management, as recently as May, highlighted BIIB092 in PSP as a key event. Raymond thinks AbbVie's failure "adds an additional element of risk" to BIIB092 and he remains Neutral on Biogen shares. The stock in morning trading is down 1.5% to $234.63.
07/18/19
LEER
07/18/19
DOWNGRADE
Target $188
LEER
Market Perform
Allergan downgraded to Market Perform from Outperform at SVB Leerink
SVB Leerink analyst Marc Goodman downgraded Allergan (AGN) to Market Perform from Outperform and lowered his price target for the shares to $188 from $217. The analyst expects the stock to trade based on the AbbVie (ABBV) deal dynamics and no longer on fundamentals. Under the terms of the agreement, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share that they hold, for a total consideration of $188.24, Goodman tells investors in a research note.
08/07/19
LEHM
08/07/19
NO CHANGE
Target $188
LEHM
Equal Weight
Allergan price target raised to $188 from $176 at Barclays
Barclays analyst Balaji Prasad raised his price target for Allergan (AGN) to $188 from $176 to reflect AbbVie's (ABBV) offer price as he assumes the acquisition is set for completion. He keeps an Equal Weight rating on Allergan shares.
VIAB Viacom
$30.01

-0.78 (-2.53%)

04/08/19
LOOP
04/08/19
NO CHANGE
Target $59
LOOP
Buy
CBS Q1 to be impacted by higher content costs, says Loop Capital
Loop Capital analyst Alan Gould kept his Buy rating and $59 price target on CBS (CBS), saying that while he is lowering his Q1 earnings outlook by 3c to $1.37 due to higher programming costs at Showtime, he is keeping a positive view on the stock given its valuation of just 9-times forward earnings. The analyst adds that CBS and Viacom (VIAB) may reopen merger talks with the AT&T renewal having been completed.
08/01/19
OTRG
08/01/19
NO CHANGE
OTRG
Broadcast and cable upfront pricing higher than expected, says OTR Global
OTR Global said its checks with U.S. media buyers and ad executives indicated that broadcast and cable networks increased upfront ad unit pricing higher than buyers expected. 2019 upfront prices were up 7%-10% year-over-year for broadcast and up 6%-9% year-over year for cable, exceeding sources' expectations of flat or slightly higher pricing, the firm noted, citing its checks.
08/09/19
08/09/19
NO CHANGE

CBS, Viacom closer to merger after agreeing to board, Bloomberg reports
CBS (CBS) and Viacom (VIAB) are near a merger deal after agreeing on the structure of the combined company's board, Nabila Ahmed and Gerry Smith of Bloomberg report, citing people familiar with the matter. The companies are still negotiating the exchange ratio of the potential all-stock merger, which could delay an announcement, sources told Bloomberg. Shari Redstone could become chairman of the combined entity, they added.
04/22/19
LOOP
04/22/19
NO CHANGE
Target $65
LOOP
Buy
CBS price target raised to $65 from $59 at Loop Capital
Loop Capital analyst Alan Gould raised his price target on CBS (CBS) to $65 and kept his Buy rating, saying the stock represents the "most attractive opportunity in large-cap media." The analyst expects the resolution around the appointment of a permanent CEO by the company to lead to CBS entering merger talks with Viacom (VIAB) within 60 days, even though the board appears to be having a "difficult time attracting outside candidates due to the uncertainty of a potential merger," with its initial March 31st target date to conclude its CEO search now having passed.

TODAY'S FREE FLY STORIES

CMCSA

Comcast

$43.17

0.82 (1.94%)

, AEO

American Eagle

$15.40

0.63 (4.27%)

19:34
08/18/19
08/18
19:34
08/18/19
19:34
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

CMCSA

Comcast

$43.17

0.82 (1.94%)

AEO

American Eagle

$15.40

0.63 (4.27%)

MO

Altria Group

$46.48

1 (2.20%)

CMCSK

Comcast

$0.00

(0.00%)

GO

Grocery Outlet

$46.55

2.81 (6.42%)

RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

BP

BP

$36.27

0.22 (0.61%)

XOM

Exxon Mobil

$68.30

1.06 (1.58%)

MYGN

Myriad Genetics

$25.36

2.14 (9.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 04

    Sep

  • 25

    Sep

  • 25

    Sep

  • 27

    Oct

  • 13

    Nov

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

19:27
08/18/19
08/18
19:27
08/18/19
19:27
Periodicals
Trump does not want to do business with Huawei, Reuters reports »

President Donald Trump…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XYF

X Financial

$2.61

0.04 (1.56%)

19:25
08/18/19
08/18
19:25
08/18/19
19:25
Earnings
X Financial reports Q2 EPS 31c, consensus 22c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

VJET

Voxeljet

$1.64

-0.05 (-2.96%)

18:44
08/18/19
08/18
18:44
08/18/19
18:44
Recommendations
Voxeljet analyst commentary at Piper Jaffray »

Voxeljet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

$0.00

(0.00%)

, AAPL

Apple

$206.44

4.71 (2.33%)

18:40
08/18/19
08/18
18:40
08/18/19
18:40
Periodicals
Apple CEO warns Trump about China tariffs, Reuters reports »

President Donald Trump…

SSNLF

Samsung

$0.00

(0.00%)

AAPL

Apple

$206.44

4.71 (2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

T

AT&T

$34.98

0.64 (1.86%)

, CMCSA

Comcast

$43.17

0.82 (1.94%)

18:05
08/18/19
08/18
18:05
08/18/19
18:05
On The Fly
Box Office Battle: 'Good Boys' wins weekend with $21M debut »

"Box Office Battle" is…

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$55.72

0.64 (1.16%)

LGF.A

Lionsgate

$11.06

0.02 (0.18%)

LGF.B

Lionsgate

$10.52

0.01 (0.10%)

DIS

Disney

$135.19

1.79 (1.34%)

VIAB

Viacom

$26.02

0.09 (0.35%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 23

    Oct

  • 27

    Oct

SFTBF

SoftBank

$0.00

(0.00%)

, SFTBY

SoftBank

$0.00

(0.00%)

17:59
08/18/19
08/18
17:59
08/18/19
17:59
Periodicals
Softbank plans to lend up to $20B to employees to invest in new fund, WSJ says »

Softbank is planning to…

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

16:50
08/18/19
08/18
16:50
08/18/19
16:50
Periodicals
Trump administration to give Huawei more time to work with U.S. clients,WSJ says »

The Trump administration…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JSAIY

J Sainsbury

$0.00

(0.00%)

16:46
08/18/19
08/18
16:46
08/18/19
16:46
Periodicals
J Sainsbury's not talking to internal candidates for CEO succession,Reuters says »

J Sainsbury's is not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$219.92

4.27 (1.98%)

16:39
08/18/19
08/18
16:39
08/18/19
16:39
Hot Stocks
Tesla relaunching solar-panel business with no-contract rentals »

Tesla is now offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 23

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

16:14
08/18/19
08/18
16:14
08/18/19
16:14
Periodicals
White House says no recession in sight, Reuters reports »

White House officials…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$89.46

0.91 (1.03%)

16:11
08/18/19
08/18
16:11
08/18/19
16:11
Periodicals
Novartis executive sold shares before data manipulation made public,Reuters says »

An unnamed Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

MO

Altria Group

$46.48

1 (2.20%)

16:08
08/18/19
08/18
16:08
08/18/19
16:08
Periodicals
CDC investigating lung illness linked to e-cigarette use, Reuters reports »

The Centers for Disease…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFB

CrossFirst Bancshares

$14.61

(0.00%)

, JFU

9F Inc

$10.09

0.52 (5.43%)

08:48
08/18/19
08/18
08:48
08/18/19
08:48
On The Fly
Opening Day: CrossFirst rises after setting IPO share price lower than expected »

Shares of CrossFirst…

CFB

CrossFirst Bancshares

$14.61

(0.00%)

JFU

9F Inc

$10.09

0.52 (5.43%)

NET

Cloudflare

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

SDC

SmileDirectClub

$0.00

(0.00%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

MSFT

Microsoft

$136.13

2.39 (1.79%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 27

    Oct

CBS

CBS

$43.83

0.5 (1.15%)

, VIA

Viacom

$27.27

-0.4 (-1.45%)

08:03
08/17/19
08/17
08:03
08/17/19
08:03
Periodicals
Viacom-CBS merger got panned by investors, Barron's says »

CBS (CBS) and Viacom…

CBS

CBS

$43.83

0.5 (1.15%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

VIAB

Viacom

$26.02

0.09 (0.35%)

AAPL

Apple

$206.44

4.71 (2.33%)

DIS

Disney

$135.19

1.79 (1.34%)

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

NFLX

Netflix

$302.74

6.81 (2.30%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

  • 27

    Oct

MYGN

Myriad Genetics

$25.36

2.14 (9.22%)

07:57
08/17/19
08/17
07:57
08/17/19
07:57
Periodicals
Myriad Genetics stock might have an FDA issue, Barron's says »

Myriad Genetics plunged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CSCO

Cisco

$46.96

0.73 (1.58%)

, NTAP

NetApp

$46.75

0.33 (0.71%)

07:50
08/17/19
08/17
07:50
08/17/19
07:50
Periodicals
Trade war hitting tech stocks, Barron's says »

Cisco (CSCO) plunged 9% a…

CSCO

Cisco

$46.96

0.73 (1.58%)

NTAP

NetApp

$46.75

0.33 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

  • 10

    Oct

  • 13

    Nov

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

, RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

07:47
08/17/19
08/17
07:47
08/17/19
07:47
Periodicals
Investors should not abandon oil, gas stocks, Barron's says »

Energy stocks have rarely…

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

BP

BP

$36.27

0.22 (0.61%)

XOM

Exxon Mobil

$68.30

1.06 (1.58%)

CVX

Chevron

$115.79

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 25

    Sep

TGT

Target

$84.20

1.67 (2.02%)

, WMT

Walmart

$112.99

0.32 (0.28%)

07:40
08/17/19
08/17
07:40
08/17/19
07:40
Periodicals
Grocery Outlet thriving as rivals struggle, Barron's says »

While Dow was down 800…

TGT

Target

$84.20

1.67 (2.02%)

WMT

Walmart

$112.99

0.32 (0.28%)

GO

Grocery Outlet

$46.55

2.81 (6.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

AEO

American Eagle

$15.40

0.63 (4.27%)

07:33
08/17/19
08/17
07:33
08/17/19
07:33
Periodicals
American Eagle to soar despite trade war, Barron's says »

American Eagle's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 25

    Sep

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

, MTCH

Match Group

$84.53

2.08 (2.52%)

07:27
08/17/19
08/17
07:27
08/17/19
07:27
Periodicals
Dating business might be IAC's best asset, greatest challenge, Barron's says »

IAC (IAC) has rallied 34%…

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

MTCH

Match Group

$84.53

2.08 (2.52%)

IAC

IAC

$249.17

4.21 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 10

    Sep

  • 10

    Oct

AAPL

Apple

$206.44

4.71 (2.33%)

, HAS

Hasbro

$114.29

1.13 (1.00%)

07:13
08/17/19
08/17
07:13
08/17/19
07:13
On The Fly
Week in review How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$206.44

4.71 (2.33%)

HAS

Hasbro

$114.29

1.13 (1.00%)

MAT

Mattel

$10.74

(0.00%)

AGR

Avangrid

$49.29

0.37 (0.76%)

JPM

JPMorgan

$107.73

2.52 (2.40%)

BAC

Bank of America

$27.04

0.79 (3.01%)

C

Citi

$63.46

2.13 (3.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 09

    Sep

  • 02

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 27

    Oct

NCLH

Norwegian Cruise Line

$50.48

1.38 (2.81%)

18:04
08/16/19
08/16
18:04
08/16/19
18:04
Hot Stocks
Norwegian Cruise Line CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RM

Regional Management

$27.12

0.14 (0.52%)

18:01
08/16/19
08/16
18:01
08/16/19
18:01
Hot Stocks
Regional Management CFO buys 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

RTN

Raytheon

$178.10

-0.42 (-0.24%)

17:59
08/16/19
08/16
17:59
08/16/19
17:59
Hot Stocks
Raytheon awarded $199.59M Navy contract for MK 15 CIWS »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.